Advertisement

Topics

Companies Related to "Perspectives Upadacitinib Rheumatoid Arthritis Report Updated 01082018 Prices" [Most Relevant Company Matches] RSS

04:58 EDT 23rd March 2019 | BioPortfolio

Here are the most relevant search results for "Perspectives Upadacitinib Rheumatoid Arthritis Report Updated 01082018 Prices" found in our extensive corporate database of over 50,000 company records.

Showing "Perspectives Upadacitinib Rheumatoid Arthritis Report Updated 01082018 Prices" Companies 1–25 of 819

Extremely Relevant

Enbrel® (etanercept)

Enbrel® (etanercept) is a TNF inhibitor approved for the following indications: moderately to severely active rheumatoid arthritis, polyarticular-course juvenile rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (arthritis of the spine) and psoriasis.


Relevant

Plexxikon Inc.

Plexxikon is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company’s lead compound, PLX4032, is in late-stage clinical trials for the treatment of melanoma. Other clinical-stage programs include PLX5568 for the treatment of polycystic kidney disease, PLX204 for the treatment ...

International Foundation for Autoimmune Arthritis

The International Foundation for Autoimmune Arthritis (IFAA) was established in 2010 after its founder, Tiffany Westrich, was diagnosed with Rheumatoid Arthritis. She united with other autoimmune arthritis patients who were also current or former business executives and educators, creating the first global nonprofit for these diseases. IFAA is committed...


Protalex, Inc.

Protalex, Inc. is a clinical stage biopharmaceutical company that is developing a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including but not limited to, rheumatoid arthritis. Protalex’s lead product PRTX-100, which is formulated with a highly-purified form of staphylococcal protein A, has completed a Phase 1b...

Arthritis Foundation, Southern California Chapter

Established in 1948, the Arthritis Foundation is the only national voluntary organization that works on behalf of people with all forms of arthritis. The Arthritis Foundation funds research to find cures and improve care, issues up-to-date information about arthritis and its treatment, and offers exercise and support groups for those with arthritis. For more information, please call 1.800.954.2873...

The Center for Biosimilars

The Center for Biosimilars® is a digital resource that serves as a platform for health economic experts, managed care professionals, key clinical specialists and other authoritative industry voices, to share information on emerging technologies, with a focus on improving critical thinking in the field to affect patient outcomes. The Center for Bi...

Protalex

Protalex (OTC:PRTX) is a biotechnology company developing a novel, new class of drugs for the treatment of various autoimmune disorders. The company’s lead compound, PRTX-100, is currently in development for idiopathic thrombocytopenic purpura, a rare blood clotting disorder, and rheumatoid arthritis. PRTX-100, a highly-purified form of Staphylococcal Protein A (SpA or Protein A) has been used ...

The Arthritis Foundation, Southeast Region, Georgia Office

The Arthritis Foundation (www.arthritis.org) is the leading health organization addressing the needs of the 46 million Americans, including 300,000 children, living with arthritis, the nation's most common cause of disability. The Foundation helps individuals take control of arthritis by providing public health education; pursuing public policy and legislation; supporting research and conducting e...

ModiQuest Research

Monoclonal Antibody Therapeutics and Diagnostics For Rheumatoid Arthritis & Cancer ModiQuest Group was founded in 2004 and is based in Nijmegen, The Netherlands. It consists of ModiQuest Therapeutics B.V, focused on the development of novel monoclonal antibody therapeutics and diagnostics for autoimmune and oncology targets, and ModiQuest Research, which provides technology and contract re...

Rigel Pharmaceuticals

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and cancer, as well as viral and metabolic diseases. Our goal is to file one new investigational new drug (IND) application in a significant indication each year. We have achieved this goal since 2002. Our pioneering research focuses on intracellu...

SFA Therapeutics

SFA Therapeutics is a bio-pharmaceutical company focused on new advancements in the treatment of inflammatory diseases, targeting NF-κB. Chronic inflammation has been implicated in a wide range of diseases, including rheumatoid arthritis, psoriatic arthritis, lupus (SLE), inflammatory bowel disease (IBD), Crohn's Disease, psoriasis, liver disease a...

Health Perspectives Group

The Health Perspectives Group of companies creates healthcare engagement and technology solutions to capture and promote the consumer perspective, making compliant, patient-centered action possible. By elevating the healthcare conversation, Health Perspectives Group believes consumers will gain the knowledge and confidence they need to navigate the complex...

Ignyta, Inc.

Ignyta, Inc., located in San Diego, California, is a personalized medicine company developing revolutionary new products and services to customize diagnosis and treatment of patients with rheumatoid arthritis, lupus and other autoimmune diseases.

Johnson and Johnson (France)

Our pharmaceuticals companies offer medicines that treat many of the world's most serious and widespread diseases. These diseases range from cancer, HIV/AIDS and bacterial infections to schizophrenia, epilepsy, rheumatoid arthritis and psoriasis. In 2007, we invested $5.3 billion in the search for new ways to treat these diseases and many others. It’s all part of our commitment to helping you an...

Cartela AB

Cartela is a biotech company dedicated to the development of innovative therapies in arthritic diseases, primarily osteoarthritis and rheumatoid arthritis. There is still no curative treatment available for arthritic diseases and current treatment options for associated chronic pain are insufficient. A new therapeutic approach is therefore highly needed.Cartela's business is based on the cell surf...

BIOTECTID GmbH

"Biotectid is specialized in the development and production of innovative in vivo diagnostics for medical imaging of chronic inflammation diseases. The main indication of which is rheumatoid arthritis (joint rheumatism). The company maintains an in-house GMP-production plant for IMP""s. The lead-product is already in clinical trials."

ENBREL

ENBREL is a type of protein called a tumor necrosis factor (TNF) blocker that blocks the action of a substance your body's immune system makes called TNF. People with an immune disease, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis, have too much TNF in their bodies. ENBREL can reduce the amount of TNF in the body to normal levels, helping to treat your d...

HealthLeaders-InterStudy

Health Plan Analysis identifies key health plan trends, allowing pharmaceutical companies to create comprehensive strategic plans and sales strategies at state and local levels. Updated quarterly and covering 35 states plus the District of Columbia, each report provides a detailed look at:

BIOTECH Patent News

BIOTECH Patent News is a monthly printed publication that keeps you updated on the latest events in the world of patented biotechnology. This site provides updates on the latest headlines from BIOTECH Patent News, summaries of recently issued US patents, descriptions of biotechnology available for license, and recent commentary and reviews by biotechology legal professionals. BIOTECH Patent Report...

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is scheduled to enter Phase III trials in 2...

BioMedical Research Models Incorporated (BRM)

Biomedical Research Models, Inc. (BRM) is a full service Contract Research Organization. We specialize in value added studies using our propriety model systems. BRM conducts studies on the efficacy of new drugs to improve Type 1 and Type 2 diabetes, diabetic complications, cancer, rheumatoid arthritis and auto-immune disease.

AtheroGenics Incorporated

AtheroGenics is an emerging pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, rheumatoid arthritis and asthma. AtheroGenics has cultivated a drug discovery and development capability directed toward rapidly creating and transporting small molecule therapeutics into the clini...

Chelsea Therapeutics

We are a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of a variety of human diseases. Our strategy is to develop technologies that address important unmet medical needs or offer improved, cost-effective alternatives to current methods of treatment. Specifically, Chelsea concentrates its efforts on acquiring and developing technologi...

ARC Pharmaceuticals Inc

ARC Pharmaceuticals Inc. is a privately owned biotechnology company developing innovative medical products for the treatment of proliferative diseases. The Company holds exclusive intellectual property related to the treatment of surgical adhesions, rheumatoid arthritis, osteoarthritis and psoriasis. ARC's initial focus is on the prevention of surgical adhesion disease, a major complication in a...

Biogen Idec Inc.

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients worldwide benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple scleros...


More From BioPortfolio on "Perspectives Upadacitinib Rheumatoid Arthritis Report Updated 01082018 Prices"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks